Details for New Drug Application (NDA): 202219
✉ Email this page to a colleague
The generic ingredient in LITHIUM CARBONATE is lithium carbonate. There are fifteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
Summary for 202219
Tradename: | LITHIUM CARBONATE |
Applicant: | Mylan Pharms Inc |
Ingredient: | lithium carbonate |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Suppliers and Packaging for NDA: 202219
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LITHIUM CARBONATE | lithium carbonate | TABLET, EXTENDED RELEASE;ORAL | 202219 | ANDA | Mylan Pharmaceuticals Inc. | 0378-1450 | 0378-1450-01 | 100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-1450-01) |
LITHIUM CARBONATE | lithium carbonate | TABLET, EXTENDED RELEASE;ORAL | 202219 | ANDA | Mylan Institutional Inc. | 51079-142 | 51079-142-20 | 100 BLISTER PACK in 1 CARTON (51079-142-20) / 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (51079-142-01) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 450MG | ||||
Approval Date: | Aug 8, 2012 | TE: | AB | RLD: | No |
Complete Access Available with Subscription